Safety, Efficacy, and Biomarker Analysis of a Phase 1 Study of PLK1 Onvansertib + Low-Dose Cytarabine or Decitabine in Relapsed/Refractory AML

93 views
January 24, 2020
0 Comments
Login to view comments. Click here to Login
Hematologic Oncology